MILabs to provide new hybrid imaging system to Yale for advancing cardiovascular research

MILabs will provide an advanced U-SPECT⁴CT system to the Yale Translational Research Imaging Center (Y-TRIC) in New Haven-Connecticut, with support of an NIH Shared Instrument Grant for advancing their program in multimodality molecular and translational cardiovascular imaging research.

High-resolution U-SPECT⁴CT image of a mouse model of human coronary heart disease.

The MILabs U-SPECT⁴CT acquired by Y-TRIC is designed to address a broad range of non-invasive imaging research in animals, from imaging probe and translational applications development to performing multimodality anatomic, physiological, and molecular imaging, plus image registration and quantification. Yale will use the new MILabs system for targeted molecular imaging and the assessment of regional myocardial perfusion, function and metabolism in investigational studies in small animals.

Dr. Albert Sinusas, Professor of Medicine and Director Cardiovascular Imaging and Director of the Translational Research Imaging Center at Yale University expects utilizing the high-quality gated SPECT and CT functions of the U-SPECT/CT system to expand his cardiac research to areas inaccessible with other systems. Professor Sinusas, recipient of the prestigious 2008 Hermann Blumgart Award, explains:

We expect that this new hybrid imaging system will enable our laboratory to advance our effort on targeted molecular imaging and the development of non–invasive nuclear imaging strategies to study the biological processes (i.e. inflammation, angiogenesis, arteriogenesis) associated with atherosclerosis, peripheral artery disease, ischemic heart disease, and post-infarct remodeling

“With the recent addition of Adaptive X-ray CT modality with dual respiratory and cardiac gating to our fourth-generation ultra-high resolution U-SPECT platform, we have further enhanced the quantification capabilities of hybrid cardiac SPECT/CT, especially for molecularly targeted radiotracer uptake” explains Dr. F. Beekman, Founder and CEO of MILabs.